Archive · 16 Sep 2026
India's DengiAll Dengue Vaccine Could Arrive by 2027
India is testing a new dengue vaccine called DengiAll.
Dengue is an illness spread by infected mosquitoes.
The vaccine is designed to protect against all four major types of dengue virus.
It was developed in India by Panacea Biotec.
The vaccine is given in one dose.
More than 13,000 volunteers are taking part in the final-stage trial.
Researchers are still checking whether the vaccine is safe and works well.
If the trial and government reviews are successful, people could be able to use it by 2027.
The vaccine would add to mosquito-control efforts, not replace them.
The Indian Council of Medical Research plans to introduce DengiAll by 2027 if clinical trials succeed.
Panacea Biotec developed the single-dose, live-attenuated vaccine to target all four dengue serotypes.
The Phase 3 trial is being conducted at 20 Indian institutes and includes more than 13,000 volunteers.
Researchers have completed nearly a year of follow-up and hope to unblind results by the end of next year.
India recorded around 1.13 lakh dengue cases and nearly 100 deaths in 2025, according to official data.
- Who
- The Indian Council of Medical Research, Panacea Biotec, and more than 13,000 trial volunteers are involved.
- What
- India is testing DengiAll, its first indigenous dengue vaccine, for possible public use.
- When
- The vaccine could be available by 2027 if clinical trials and regulatory assessments succeed.
- Where
- The Phase 3 trial is taking place across 20 institutes in India.
- Why
- Dengue remains a significant and recurring public-health challenge in India, particularly during and after the monsoon season.
- Vaccine
- DengiAll
- Developer
- Panacea Biotec
- Dose
- Single dose
- Trial stage
- Phase 3
- Trial participants
- More than 13,000 volunteers
- Trial locations
- 20 institutes in India
- Target serotypes
- DENV-1, DENV-2, DENV-3, and DENV-4
- 2025 dengue burden
- Around 1.13 lakh cases and nearly 100 deaths, according to official data